Nebenwirkungen · Imbruvica
IMBRUVICA 140 mg film-coated tablets IMBRUVICA 280 mg film-coated tablets IMBRUVICA 420 mg film-coated tablets IMBRUVICA 560 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 53–54
HOS-131651 · Präparat HOS-097103
53 Tabulated list of adverse reactions Adverse reactions in patients treated with ibrutinib for B-cell malignancies and post-marketing adverse reactions are listed below by system organ class and frequency grouping. Frequencies are defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1 000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:30:00Z · SHA-256 a9cee31168a81381e2e0315390c7e6008548b2272679979bce5eb1784595366b · Passage cc205e8294cd145eff37a5a10f5b333ad2ec632b6896059cc7e82da53624dc18 · Zeichen 432–951 im Abschnitt